Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592)
intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants
<2 years of age with invasive fungal infection (IFI).